Strategy, Marketing & Business Development (Nasdaq: Immc)
Us
European Business Development, Marketing, strategy & economic analysis projects. Patent valuation of IMMC's immunoassay assets & non-core areas of interest for IMMC asset sales. Strategic projects to guide IMMC's go-to-market options for Immunicon's CEOs. Business development for immunoassay & MRI with bioMérieux SA, Geurbet SA and Sweden's Nycomed Pharmaceutical.Immunicon (NASDAQ: IMMC) developed & commercialized CELLSEARCH, the world's only FDA-approved suite of circulating tumor cell (CTC) assays for monitoring epithelial cell-based cancers: metastatic breast, prostate & CRC cancers. Immunicon’s founder, CEO and chief scientist, Paul A. Liberti, developed Immunicon’s class of biologically-active nanomagnetic particles (ferrofluids) at the heart of CELLSEARCH’s CTC cancer & rare cell diagnostic assays. CELLSEARCH's rare cell isolation technology & downstream molecular-based diagnostics provide key analytical services to pharma & biotech for determining the efficacy of new cancer drug compounds in the clinic.In 2008, Johnson & Johnson’s cancer diagnostics division VERIDEX (now Janssen Diagnostics) acquired Immunicon and its path-breaking CELLSEARCH technology. Janssen Diagnostics markets CELLSEARCH for both cancer disease management & cancer lead development in the clinic, see https://www.cellsearchctc.com/CELLSEARCH's platform identifies, counts and characterizes very small number of rare blood cells, such as CTCs and circulating endothelial cells (CECs). CELLSEARCH's platform has also been applied to CEC isolation for cardiovascular disease prevention & management.In 2009, VERIDEX accepted the very prestigious Prix-GALIEN for Immunicon's path-breaking invention & CELLSEARCH product development for the Best Medical Technology 2009, see http://bit.ly/CellSearchPrixGalien The CellSearch CTC assay suite of products remain the only FDA-approved test for monitoring CTCs.Immunicon raised $85M in its 2004 NASDAQ IPO - see http://bit.ly/Immunicon_IPO_NASDAQ